A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
Latest Information Update: 02 May 2023
At a glance
- Drugs Ninerafaxstat (Primary)
- Indications Angina pectoris
- Focus Adverse reactions; Therapeutic Use
- Sponsors Imbria Pharmaceuticals
Most Recent Events
- 27 Apr 2023 Planned End Date changed from 29 Apr 2023 to 1 Feb 2025.
- 27 Apr 2023 Planned primary completion date changed from 28 Feb 2023 to 1 Feb 2025.
- 27 Apr 2023 Status changed from not yet recruiting to suspended.